氟哌噻吨美利曲辛联合右佐匹克隆治疗慢性紧张型头痛的临床疗效分析

发布时间：2019-05-14 23:35

【摘要】：目的探讨氟哌噻吨美利曲辛联合右佐匹克隆治疗伴抑郁及失眠症状的慢性紧张型头痛(CTTH)的临床疗效。方法选择2014年6月—2016年2月我院收治的150例伴抑郁及失眠症状的CTTH患者,按随机数字表法分为对照1组、对照2组和联合组,每组各50例。对照1组口服氟哌噻吨美利曲辛,对照2组口服右佐匹克隆,联合组采用氟哌噻吨美利曲辛和右佐匹克隆联合治疗方法。于治疗前、治疗6周后采用匹茨堡睡眠质量指数量表(PSQI)、汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)和疼痛视觉模拟评分(VAS)进行评价,比较各组临床疗效和不良反应情况。结果联合组治疗总有效率为90.00%,显著高于对照1组的58.00%(P0.05),与对照2组比较差异无统计学意义(P0.05);三组患者VAS、HAMD、HAMA和PSQI评分均较治疗前明显降低(P0.05);联合组的各项评分均显著低于对照1组(P0.05),联合组VAS、HAMD和HAMA评分低于对照2组(P0.05),PSQI评分显著低于对照2组(P0.01);治疗6周后,三组患者不良反应发生率差异无统计学意义(P0.05)。结论氟哌噻吨美利曲辛联合右佐匹克隆治疗伴抑郁及失眠症状的CTTH临床疗效显著,能够快速改善患者抑郁症状和睡眠质量,无明显不良反应,值得临床推广应用。
[Abstract]:Objective to investigate the clinical efficacy of droperidol combined with dexzopiclone in the treatment of chronic tension headache (CTTH) with depression and insomnia. Methods from June 2014 to February 2016, 150 patients with CTTH with depression and insomnia were randomly divided into control group 1 (n = 50), control group 2 (n = 50) and combined group (n = 50). The control group 1 was treated with norfloxacin and the control group 2 with right zopiclone. The combined group was treated with norfloxacin and right zopiclone. Before and 6 weeks after treatment, the Pittsburgh sleep quality index scale (PSQI), Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD) and pain visual analog score (VAS) were used to evaluate the evaluation. The clinical efficacy and adverse reactions of each group were compared. Results the total effective rate of the combined group was 90.00%, which was significantly higher than that of the control group 1 (58.00%, P 0.05). There was no significant difference between the combined group and the control group (P 0.05). The scores of VAS,HAMD,HAMA and PSQI in the three groups were significantly lower than those before treatment (P 0.05). The scores of VAS,HAMD and HAMA in the combined group were significantly lower than those in the control group 1 (P 0.05), and the), PSQI scores in the combined group were significantly lower than those in the control group 2 (P 0.01). After 6 weeks of treatment, there was no significant difference in the incidence of adverse reactions among the three groups (P 0.05). Conclusion droperidol combined with dexzopiclone is effective in the treatment of CTTH with depressive and insomnia symptoms. It can quickly improve the depressive symptoms and sleep quality of patients without obvious adverse reactions. It is worthy of clinical application.
【作者单位】：台山市人民医院;
【分类号】：R741

【参考文献】